Inhibikase Therapeutics announced that Joseph Frattaroli, Chief Financial Officer, plans to retire at the end of the first quarter of 2024. The Company’s Vice-President for Finance, Garth Lees-Rolfe, will be promoted to Chief Financial Officer. “On behalf of the Board of Directors and the entire Inhibikase team, I would like to extend our deepest gratitude to Joe for his years of service. Joe joined Inhibikase in 2018, and, through his leadership, we successfully transitioned into a public company and have managed to finance our research and development programs despite the difficult market,” said Dr. Milton Werner, President and Chief Executive Officer of Inhibikase. “While I’m sad to lose a partner and confidant, succeeding Joe in his role is Garth Lees-Rolfe, our current VP of finance, who has been working with Joe and has been assuming increased responsibilities over the past year as part of a planned transition to becoming our next Chief Financial Officer. We are excited to have Garth take on an expanded role with Inhibikase as we enter a new chapter of growth.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IKT:
- Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
- Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
- Inhibikase Therapeutics issues letter to shareholders, provides update
- Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro
- Inhibikase Therapeutics granted pre-NDA meeting with FDA for IkT-001Pro